Free account + included starter software — credential review typically takes 1–2 business days. See how it works
METHOCARBAMOL 500MG 500 TAB - 500 mg/1 TABLET, COATED
Request Item

METHOCARBAMOL 500MG 500 TAB

Generic: Methocarbamol Tablets

METHOCARBAMOL 500MG 500 TAB

NDC:70010-0754-05
Manufacturer:Granules Pharmaceuticals Inc.
Strength:500 mg/1
Dosage Form:TABLET, COATED
Route:ORAL

Sign up to see pricing

Licensed pharmacies, clinics, doctor's offices, and veterinary practices get instant account approval

Sign Up — Instant Approval

Drug Information

Identification

Generic Name

Methocarbamol Tablets

Brand Name

Methocarbamol

Labeler / Distributor

Granules Pharmaceuticals Inc.

Product Type

HUMAN PRESCRIPTION DRUG

Administration

Dosage Form

TABLET, COATED

Route of Administration

ORAL

FDA Application Number

ANDA209312

Active Ingredients

IngredientStrength
METHOCARBAMOL500 mg/1

Pharmacological Class

Centrally-mediated Muscle Relaxation [PE]Muscle Relaxant

Data sourced from openFDA / DailyMed. For full prescribing information, consult the drug label.

Clinical Drug Information

Indications & Usage

INDICATIONS AND USAGE Methocarbamol tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.

Warnings

WARNINGS Since methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol tablets, USP should be cautioned about combined effects with alcohol and other CNS depressants. Safe use of Methocarbamol tablets, USP has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, Methocarbamol tablets, USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see Precautions, Pregnancy ). Use In Activities Requiring Mental Alertness Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

Dosage & Administration

DOSAGE AND ADMINISTRATION Methocarbamol tablets, USP, 500 mg – Adults: Initial dosage: 3 tablets q.i.d. Maintenance dosage: 2 tablets q.i.d. Methocarbamol tablets, USP: 750 mg – Adults: Initial dosage: 2 tablets q.i.d. Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d. Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

Adverse Reactions

ADVERSE REACTIONS Adverse reactions reported coincident with the administration of methocarbamol include: Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headache Cardiovascular system: Bradycardia, flushing, hypotension, syncope, thrombophlebitis Digestive system: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting Hemic and lymphatic system: Leukopenia Immune system: Hypersensitivity reactions Nervous system: Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo Skin and special senses: Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria

Information for Patients

Information for patients Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery. Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

Clinical data sourced from openFDA drug labeling. For complete prescribing information, consult the full drug label.